Calls for papers
-
Dry powder nebulizer maker Nob Hill Therapeutics has named former Oriel Therapeutics President and CEO Paul Atkins as Executive Chairman. Atkins headed DPI developer Oriel until the company was acquired by Sandoz in 2010 and… Read more . . .
-
Hikma Pharmaceuticals said that the FDA has approved an amendment to the company’s ANDA for its generic version of Advair Diskus fluticasone propionate / salmeterol DPI, and the company has subsequently restarted the launch of… Read more . . .
-
Swedish aerosol research instrument maker Inhalation Sciences (ISAB) says that the company intends to expand its presence in the US in 2021 and has signed agreements with lead generation company Cience and with CRO consultant… Read more . . .
-
NeuroRx and Relief Therapeutics have each issued press releases enumerating disagreements between the companies regarding development of Zyesami aviptadil (RLF-100), a synthetic vasoactive intestinal peptide. The two companies are partnered on development of the formulation… Read more . . .
-
Covis Pharma said that a Phase 3 trial of Alvesco ciclesonide MDI for the treatment of COVID-19 in 400 patients who have not been hospitalized failed to meet its primary endpoint, which was freedom from… Read more . . .
-
United Therapeutics said that it has submitted an NDA for its Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) and has applied a priority review voucher that it acquired for $105 million… Read more . . .
-
Virpax Pharmaceuticals announced that a study of its MMS019 powder “masking spray” in mice demonstrated “a marked inhibition of viral replication in the mouse nasal passages” for mice infected with SARS-CoV-2 and then given MMS019 intranasally… Read more . . .
-
Hovione Technology’s 8Shot dry powder inhaler has been selected as a finalist for the 2021 Medical Design Excellence Awards (MDEA) in the Drug-Delivery and Combination Products category, the company said. The 8Shot DPI, which is… Read more . . .
-
Nasus Pharma said that a bioequivalence study of its FMXIN001 dry powder intranasal naloxone demonstrated that FMXIN001 was absorbed significantly faster than Emergent BioSolutions’ Narcan naloxone nasal spray, with an AUC 163% of the Narcan… Read more . . .
-
GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA